News & Events

Durham, NC, May 18, 2016 – GeneCentric Diagnostics, Inc., a company devoted to changing the taxonomy of cancer through the analysis of tumor genomics, announced today that it will present new data on its Cancer Subtyping Platform (CSP™) at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 at McCormick Place, Chicago Illinois.

CSP™, GeneCentric’s proprietary core technology, identifies biologic subtypes of cancer through an integrated analysis of tumor genomics. Cancer subtypes support rational clinical trial design as biomarkers identifying patient cohorts optimally suited for various therapeutic approaches.

Details of the presentation are as follows:

Title: “Immune cell activation among lung adenocarcinoma and squamous cell carcinoma intrinsic subtypes and CD274 (PD-L1) expression.”
Poster Number: 399
Date: Sunday, June 5
Time: 8:00 AM – 11:30 AM CT
Location: McCormick Place, Hall A
Presenter: Hawazin Faruki, DrPH, Chief Scientific Officer, GeneCentric

“We are excited to present our latest immunotherapy related findings on CSP™,” said Dr. Faruki. “We are committed to developing precision medicine tools for enhanced trial design and patient stratification.”

To read the abstract, please visit:

About GeneCentric
GeneCentric Diagnostics, Inc. is a company devoted to changing the taxonomy of cancer through an integrated analysis of tumor pathology and genomics. GeneCentric is redefining the advanced classification of cancers through the development and commercialization of its proprietary Cancer Subtype Platform (CSP™). By capturing a comprehensive picture of DNA, RNA and copy number biomarkers, CSP™ can better enable drug developers and oncologists to make more individualized treatment decisions and meet the growing demand for precision medicines. GeneCentric’s first application of CSP™ was launched with partner LabCorp® and is available as HistoPlusSM: Lung Cancer.

For more information, please visit

Contact Information:
Dr. Myla Lai-Goldman, CEO
GeneCentric Diagnostics, Inc.